Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
SoftOx Solutions AS ( (DE:6FV) ) has issued an announcement.
SoftOx Solutions AS has published its Annual Report for 2024, with the Board of Directors approving the financial statements in line with Norwegian accounting standards. This announcement underscores the company’s commitment to transparency and adherence to regulatory requirements, potentially bolstering stakeholder confidence and reinforcing its position in the pharmaceutical industry.
More about SoftOx Solutions AS
SoftOx Solutions AS is a clinical-stage pharmaceutical company listed on Euronext Growth Oslo. The company focuses on developing highly effective pan-antimicrobial pharmaceuticals targeting bacteria, viruses, and fungi, leveraging extensive research and development in collaboration with leading Nordic research institutes.
YTD Price Performance: 542.86%
Average Trading Volume: 57,630,965
Current Market Cap: NOK168M
For a thorough assessment of 6FV stock, go to TipRanks’ Stock Analysis page.